Press View database covers global pharmaceutical and biotech companies daily announcements on drug development and corporate updates.
Database covers more than 4,500 active companies that includes development and commercial drugs companies.
Customized support for the below data fields,
Provides comprehensive analysis on drug research and market innovations with key data attributes.
Drug research expenses and success rates depends on molecule type and indication,
Trend analysis covers detailed information on Companies, Drugs, Patents and Sales. Topics covered in the database are,
Paris, France and Cambridge, Mass., USA, July 9 , 2019 - NANOBIOTIX, French pioneer in nanomedicine developing new therapeutic approaches for the treatment of cancer, announces that the results of Phase II / III of the Act.In.Sarc Trial Evaluating NBTXR3 in Advanced Soft Tissue Sarcomas previously presented have been published online in the journal Lancet Oncology .Read more..
AUSTIN, Texas, July 09, 2019/- XBiotech today announced that the United Kingdom Research and Innovation (UKRI) Medical Research Council (MRC) is funding for the Bermekimab study. Therapy in a multicenter Phase 2 study in advanced cancer. The MRC will cover all clinical costs of the Phase 2 study in the treatment of patients with advanced lung, pancreatic and ovarian cancer.Read more..
SUMMIT, N.J., July 09, 2019/-- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people with epilepsy who experience a predictable pattern of seizures, today announced that data from a phase 2a study of Staccato® alprazolam to suppress seizures in patients with epilepsy were published in the peer-review journal Epilepsia.Read more..
STAMFORD, Conn., July 09, 2019/-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with atopic dermatitis (AD)Read more..